Palisade Bio (PALI) Accumulated Expenses (2010 - 2026)
Palisade Bio (PALI) posted quarterly Accumulated Expenses of $122000.0 for Q1 2026, up 3.39% year-over-year from $118000.0 in Q1 2025, and down 90.6% quarter-over-quarter from $1.3 million in Q4 2025.
Palisade Bio (PALI) Accumulated Expenses (2010 - 2026) Analysis & Trends
Palisade Bio (PALI) has reported Accumulated Expenses for 16 consecutive years, with $122000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses rose 3.39% year-over-year to $122000.0; the TTM figure through Mar 2026 stood at $122000.0 (up 3.39% YoY), while the FY2025 annual figure was $1.3 million, up 79.78% from the prior year.
- Accumulated Expenses fell to $122000.0 in Q1 2026 per PALI's latest filing, from $1.3 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $1.3 million in Q4 2025 and bottomed at $72000.0 in Q1 2022.
- Historically, Accumulated Expenses has averaged $417941.2 across 5 years, with a median of $309000.0 in 2023.
- Annual changes were most pronounced in 2022 — Accumulated Expenses slumped 73.75% — and 2023, when it jumped 686.84%.
- Palisade Bio's Accumulated Expenses stood at $574000.0 in 2022, then jumped by 44.77% to $831000.0 in 2023, then declined by 13.12% to $722000.0 in 2024, then jumped by 79.78% to $1.3 million in 2025, then slumped by 90.6% to $122000.0 in 2026.
- Business Quant data shows PALI's Accumulated Expenses at $122000.0 in Q1 2026, $1.3 million in Q4 2025, and $621000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Palisade Bio | 372.94 Mn | 247.74 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.14 Mn |
| Mar 31, 2026 | 122,000.00 |
| Dec 31, 2025 | 1.30 Mn |
| Sep 30, 2025 | 621,000.00 |
| Jun 30, 2025 | 192,000.00 |
| Mar 31, 2025 | 118,000.00 |
| Dec 31, 2024 | 722,000.00 |
| Sep 30, 2024 | 449,000.00 |
| Jun 30, 2024 | 288,000.00 |
| Mar 31, 2024 | 213,000.00 |
| Dec 31, 2023 | 831,000.00 |
| Sep 30, 2023 | 529,000.00 |
| Jun 30, 2023 | 598,000.00 |
| Mar 31, 2023 | 309,000.00 |
| Dec 31, 2022 | 574,000.00 |
| Sep 30, 2022 | 93,000.00 |
| Jun 30, 2022 | 76,000.00 |
| Mar 31, 2022 | 72,000.00 |
| Dec 31, 2021 | 463,000.00 |
| Sep 30, 2021 | 89,000.00 |